Keywords: gsk, gives, up, avandia, formulation, patent, china
GSK gives up on one Avandia formulation patent in China
Article | 23 August 2004
UK drug giant GlaxoSmithKline has waived its rights to a Chinesepatent on its blockbuster antidiabetic drug Avandia (rosiglitazone), which achieved ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
